---
canonical_name: Vesugen
alternate_names: KED, KED Peptide, Lys-Glu-Asp, T-38, Vezugen
canonical_topic: Vesugen for Health & Longevity
short_topic_lc: vesugen
creation_date: 2026-0831-2226
creator_ai_fullname: Opus 5
ep_keywords: Bioregulator Peptides, Khavinson Peptides, Peptides
---

# Vesugen for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 08/31/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5

**Also known as:** KED, KED Peptide, Lys-Glu-Asp, T-38, Vezugen

  
## Motivation

<!-- This motivation section was written last, after every other section of this review was complete, so that it reflects the full scope of what the evidence does and does not show. -->

Vesugen is a synthetic peptide made of just three amino acids — lysine, glutamic acid and aspartic acid — sold as a supplement aimed at the lining of blood vessels. It comes from a Russian family of very short peptides marketed as "bioregulators", built on the idea that a fragment this small can enter a cell nucleus and shift the activity of a few specific genes back toward a younger pattern.

The compound was created at a St. Petersburg gerontology institute in the late 1990s, patented in Russia in 2007 for improving the resilience of small blood vessels, and has been sold there ever since as a food supplement. It has never been approved as a medicine anywhere, and outside Russia it circulates mainly through laboratory-chemical suppliers whose labels say it is not for human use.

This review examines what has actually been measured: the laboratory findings behind the blood-vessel claims, the small human studies run almost entirely by the group that created and sells the compound, what is known and unknown about how it behaves in the body, and how the supply channel shapes what someone would in practice be taking.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

High-level treatments of Vesugen or of the unapproved-peptide category it belongs to, from expert and academic sources.

<!-- Real-time searches performed 31 August 2026. Web searches were run for "Vesugen", "KED peptide bioregulator Khavinson", and for each priority expert paired with the intervention and with "peptide bioregulator". On-site searches were run directly: foundmyfitness.com (site search, "peptide bioregulator" - no results found), peterattiamd.com (site search, "peptides" and "Khavinson"), hubermanlab.com (site search, "peptide"), lifespan.io (site search, "Khavinson" - one article on a different peptide, Epitalon, in an oocyte model), lifeextension.com and chriskresser.com (domain-restricted web search). Vendor blogs, peptide-shop explainers and research-chemical product pages dominate the general web results for this compound and were excluded as commercial material rather than expert commentary. -->

* [#403 ‒ Peptides: separating scientific promise from marketing hype](https://peterattiamd.com/peptides/) - Peter Attia

  Vesugen sits squarely in the unapproved gray-market peptide category this episode dissects; Attia's five-question framework — mechanism, human benefit, safety and dosing, risk versus benefit, better-characterised alternatives — applies to it directly.

* [Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity](https://www.hubermanlab.com/episode/dr-craig-koniver-peptide-hormone-therapies-for-health-performance-longevity) - Andrew Huberman

  A practitioner's account of how the same unapproved-peptide category is actually deployed — sourcing, compounding, dosing and monitoring — a clinical perspective entirely absent from the Russian literature on Vesugen.

* [Peptide bioregulation of aging: results and prospects](https://pubmed.ncbi.nlm.nih.gov/19830585/) - Anisimov & Khavinson, 2010

  The founding narrative review of the Khavinson short-peptide programme that produced Vesugen, summarising the rodent lifespan and tumour findings; note that its authors' institute also patents and sells these products.

Only three items qualified, and this is stated plainly rather than padded. No article, episode or lecture on Vesugen, on its tripeptide, or on the Khavinson bioregulator class exists on foundmyfitness.com, chriskresser.com or lifeextension.com; lifespan.io's single related item covers a different peptide of the same family in a fertility model and does not treat this compound or its mechanism in depth. The remaining web results for this compound are vendor product pages and peptide-shop explainers, which are marketing rather than evidence.

  
## Grokipedia

<!-- grokipedia.com was searched directly with the browser tool on 1 September 2026: the site search for "Vesugen" returns exactly one result, the compound's own dedicated article at /page/Vesugen, which loads in full and is marked fact-checked by Grok. -->

[Vesugen](https://grokipedia.com/page/Vesugen)

The site's dedicated entry on the compound, covering its chemistry, Khavinson-programme history, proposed epigenetic mechanism, biological effects and regulatory status, with references to the underlying Russian literature.

  
## Examine

<!-- examine.com was searched directly with the browser tool on 31 August 2026. The site search for "Vesugen" returned "Sorry, there are no search results for Vesugen." -->

No Examine article exists for Vesugen. A direct search of examine.com on 31 August 2026 returned no results for the compound under any of its names.

  
## ConsumerLab

<!-- consumerlab.com was searched directly with the browser tool on 31 August 2026. The site search for "Vesugen" returned "Sorry, we didn't find any results for Vesugen." -->

No ConsumerLab article exists for Vesugen. A direct search of consumerlab.com on 31 August 2026 returned no product review, answer or clinical update mentioning the compound, which has never been included in its testing programme.

  
## Systematic Reviews

<!-- PubMed was searched on 31 August 2026 with the following strategies: "Vesugen"; "Vesugen OR Lys-Glu-Asp OR KED peptide"; "(peptide bioregulator OR short peptide OR Khavinson) AND (systematic review[pt] OR meta-analysis[pt])"; "(peptide OR bioregulator) AND (aging OR geroprotector) AND systematic review[pt]"; and "Khavinson peptide regulation gene expression systematic review". Across those strategies exactly two records carry the PubMed publication type "Systematic Review", and both are listed below. Selection was by relevance and publication type; citation counts are not available for this literature. -->

Systematic reviews and meta-analyses indexed on PubMed that bear on Vesugen or the short-peptide class it belongs to.

* [Peptide Regulation of Gene Expression: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/34834147/) - Khavinson et al., 2021

  Maps how short peptides are proposed to bind DNA promoter regions; the indexed systematic review closest to Vesugen's peptide, written by its developers.

* [How short peptides interact with oral cells? A systematic review](https://pubmed.ncbi.nlm.nih.gov/40197322/) - Tetè et al., 2025

  The only synthesis of this class produced independently of the developers; it appraises the Vesugen tripeptide senescence-marker study among eight in vitro papers.

The trade-off is unevenly represented. Both indexed systematic reviews address the claimed mechanism and laboratory effects, not clinical outcomes, and nothing on the risk side — the safety of short peptide bioregulators, or the quality of the unregulated peptide supply channel — has been synthesised at all: no systematic review or meta-analysis of either exists on PubMed. The first was produced by the St. Petersburg Institute of Bioregulation and Gerontology, which developed, patented and sells Vesugen, so the party with a direct financial interest in the conclusions wrote the only synthesis that treats the claimed mechanism directly.

  
## Mechanism of Action

Vesugen is the tripeptide Lys-Glu-Asp, abbreviated KED. The proposed mechanism is epigenetic (changing which genes are switched on without altering the DNA sequence itself) rather than receptor-based: a molecule this small is thought to pass into the nucleus and bind the minor groove of double-stranded DNA at short motifs. Molecular docking places KED on the CATC and CACC sequences inside the promoter of MKI67, the gene encoding Ki-67 (a protein produced only by dividing cells), with binding energies around −7 to −8 kcal/mol ([Khavinson et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25051766/)). Fluorescent-label work on sibling peptides confirms that short peptides reach the nucleus and nucleolus of human cells and discriminate between DNA sequences ([Fedoreyeva et al., 2011](https://pubmed.ncbi.nlm.nih.gov/22117547/)).

Downstream, aged endothelial (blood-vessel lining) cultures exposed to KED show normalised endothelin-1 (a signal that constricts vessels), restored connexin (the proteins forming channels between neighbouring cells) and higher SIRT1 (an enzyme involved in DNA repair) ([Kozlov et al., 2016](https://pubmed.ncbi.nlm.nih.gov/28539025/)), and more Ki-67 ([Khavinson et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25051766/)).

A competing explanation is that no sequence-specific step is needed: three free amino acids released by digestion could account for a non-specific growth-supporting effect, and no experiment has separated the intact tripeptide from its breakdown products in humans.

Key pharmacological properties are unpublished. Half-life, selectivity, tissue distribution and metabolising enzymes have never been measured for Vesugen; peptides of this length are expected to be cleaved by brush-border and plasma peptidases within minutes, and no cytochrome P450 (a liver enzyme family that clears most drugs) pathway is implicated.

  
## Historical Context & Evolution

Vesugen descends from a Soviet military-medicine programme. In the 1970s, at the Kirov Military Medical Academy in Leningrad, Vladimir Khavinson and Vyacheslav Morozov extracted crude polypeptide fractions ("cytomedins") from calf thymus and pineal gland to restore immune function in irradiated and injured personnel; the resulting preparations Thymalin and Epithalamin entered Soviet clinical use. The original purpose was therefore repair of damaged organ systems, not longevity.

The longevity framing came from the follow-on animal work. Long-term dosing with these preparations was reported to raise mean lifespan in rodents by 20–40% and to suppress both spontaneous and carcinogen-induced tumours, alongside slowed drift in ageing biomarkers ([Anisimov & Khavinson, 2010](https://pubmed.ncbi.nlm.nih.gov/19830585/)). Those are the actual findings on which the whole class rests, and they have not been retracted.

From the mid-1990s the group moved from crude extracts to defined di-, tri- and tetrapeptides synthesised to match the shortest active fragment of each extract. Vesugen is the vascular member: Lys-Glu-Asp, patented in Russia in 2007 (RU 2295970 C1) as a substance that increases capillary resistance (the ability of the smallest vessels to withstand pressure without leaking), with Khavinson named as an inventor.

What has changed since is not a refutation but a stalled verification. No laboratory outside the founding group has reproduced the lifespan results, no regulator outside Russia has reviewed a dossier, and no controlled trial of Vesugen has been registered — so the class today sits neither confirmed nor disproven.

  
## Expected Benefits

<!-- A dedicated benefit-profile search was performed before writing this section, on 31 August 2026: PubMed searches for "Vesugen", "Vesugen OR Lys-Glu-Asp OR KED peptide" (70 records), "Khavinson short peptides bioregulator vascular", and date-restricted 2023-2026 sweeps; ClinicalTrials.gov searches by intervention and free text; the full Grokipedia entry; and web searches for expert commentary. Every human, animal and in vitro outcome attributed to this compound anywhere in that corpus is represented below. -->

### High 🟩 🟩 🟩

No benefit reaches High: no randomised controlled trial of Vesugen exists, so no clinical endpoint and no validated clinical surrogate has been demonstrated in even one controlled trial, let alone more than one.

### Medium 🟩 🟩

No benefit reaches Medium either: the human data consist of open-label uncontrolled case series rather than a single controlled trial or a consistent observational dataset.

### Low 🟩

#### Peripheral Arterial Blood Flow in Atherosclerotic Vascular Insufficiency

Two open series gave Vesugen as sole treatment in patients with atherosclerosis (fatty plaque build-up in artery walls): 41 with vasculogenic (blood-flow-related) erectile dysfunction ([Kitachev et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25051774/)) and 41 after lower-limb arterial surgery ([Kitachov et al., 2013](https://pubmed.ncbi.nlm.nih.gov/28976154/)). Ultrasound flow and clinical scores improved in both; no control group, developer-affiliated.

**Magnitude:** Direction only — blood flow in the main penile arteries improved significantly on both clinical and ultrasound measures after a single monotherapy course, and lower-limb flow likewise after surgery; both published reports state significance without giving an effect-size figure for any measure.

#### Slowed Biological-Age Drift in Older Adults with Multiple Chronic Conditions

In 32 adults aged 41–83 with multiple coexisting illnesses, oral Vesugen produced an anabolic (tissue-building) effect, better central nervous system activity and a slower rate of ageing on biological-age indices ([Meshchaninov et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26390612/)). The study was open-label, uncontrolled, and reported alongside a second peptide.

**Magnitude:** Direction only — biological age advanced more slowly than chronological age across a single supplementation course in adults with existing chronic disease; the published report gives no numerical difference in years or index points.

#### Memory and Attention in Older Adults with Functional Brain Disorders

A review by the developing group states that oral KED improved memory and attention in elderly people with functional central nervous system disorders ([Khavinson et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34173097/)). No primary trial report for that claim is indexed on PubMed, so the finding cannot be independently checked.

**Magnitude:** Not quantified in available studies. The claim appears only as a summary sentence inside a review; no underlying trial with numerical cognitive results has been published in an indexed journal.

#### Psychoemotional Resilience Under Sustained Occupational Strain

In 150 professional truck drivers under occupational strain, bioregulator peptides restored adaptive capacity, improved psychoemotional indices and lowered the risk of borderline mental disorders (anxiety and exhaustion short of a formal diagnosis) ([Bashkireva & Artamonova, 2012](https://pubmed.ncbi.nlm.nih.gov/23734521/)). Vesugen was given with a second peptide, so its own share is unresolved.

**Magnitude:** Direction only — psychoemotional and adaptation indices improved significantly across a standard course in working-age men under chronic occupational strain; the published report gives significance levels but no effect size for any index.

#### Oral Mucosal Recovery after Cancer Treatment

In 22 elderly patients with chemical stomatitis (treatment-induced inflammation of the mouth lining) and reduced saliva flow after therapy for oropharyngeal tumours, adding oral Vesugen to the standard regimen was reported to improve rehabilitation ([Filippova, 2013](https://pubmed.ncbi.nlm.nih.gov/28976153/)). Uncontrolled, developer-affiliated, given with a second supplement.

**Magnitude:** Direction only — rehabilitation was reported as more effective than the standard regimen alone in post-treatment patients of advanced and senile age; the published report gives no effect-size figure for mucosal or salivary recovery.

### Speculative 🟨

#### Endothelial Cell Renewal and Signalling in Aged and Atherosclerotic Vessels

In aged rat aortic cultures KED raised Ki-67 ([Khavinson et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25051766/)); in human endothelial cultures it normalised endothelin-1, restored connexin channels and increased SIRT1 ([Kozlov et al., 2016](https://pubmed.ncbi.nlm.nih.gov/28539025/)). Culture only; no human outcome.

#### Preservation of Dendritic Spines in an Alzheimer's Mouse Model

Injection of KED at 400 µg/kg prevented loss of dendritic spines (brain-cell contact points) and trended toward better neuroplasticity in an Alzheimer's mouse ([Khavinson et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34071923/)). Animal data only, effects seen in males.

#### Neuronal Differentiation and Serotonin Signalling in Aged Nerve-Cell Cultures

KED raised the neuron-precursor markers nestin and GAP43 in human stem cells ([Caputi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30791821/)) and increased serotonin (a mood-regulating brain messenger) in ageing brain-cortex cultures ([Khavinson et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24909721/)). Culture only.

#### Delay of Cellular Senescence Markers in Human Stem Cells and Skin Fibroblasts

KED cut ageing markers p16 and p21 by 1.8–3.2-fold in oral stem cells ([Sinjari et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31677028/)) and suppressed the tissue-degrading enzyme MMP-9 (matrix metalloproteinase-9) in ageing skin fibroblasts ([Lin'kova et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27259496/)). Culture only.

#### Protection Against Low Oxygen and Oxidative Membrane Damage ⚠️ Conflicted

Animal and cell-culture data only: protection against low oxygen in animals ([Kozina, 2008](https://pubmed.ncbi.nlm.nih.gov/18546825/)) and limited oxidative fat damage with steadier red-cell membranes ([Kozina et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18546826/)). Net: the single human dataset found oxidant promotion instead.

  
## Benefit-Modifying Factors

* **Peptide transporter genetics:** No pharmacogenetic study exists. Variants in SLC15A1 (the gene encoding the intestinal transporter PepT1, which carries two- and three-amino-acid peptides across the gut wall) would plausibly determine how much of an oral dose is absorbed intact.

* **Baseline endothelial damage:** Every reported effect was larger in aged or atherosclerotic tissue than in young tissue, in both whole-tissue and single-cell cultures ([Khavinson et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25051766/)), so vessels still functioning well have the least room to gain.

* **Baseline inflammatory and lipid markers:** Those with elevated high-sensitivity C-reactive protein (a blood marker of low-grade inflammation) or apolipoprotein B have the vascular substrate the compound claims to act on; those already at target have no endpoint left to move.

* **Sex:** The only sex-stratified data come from the Alzheimer's mouse work, where the dendritic-spine density effect was significant in males and absent in females ([Khavinson et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34071923/)). No human sex analysis exists.

* **Pre-existing conditions:** Human benefit was reported only in people who already had atherosclerotic disease or several coexisting illnesses. Nothing supports a benefit in otherwise healthy adults, and no study has enrolled them.

* **Age:** Human exposure runs from working-age men in their forties to patients of 83, with the vascular and biological-age work confined to 41–83. The proposed mechanism — restoring an age-related decline in cell renewal — predicts a larger effect at the older end.

  
## Potential Risks & Side Effects

<!-- A dedicated side-effect search was performed before writing this section, on 31 August 2026. No drug reference monograph exists for this compound: drugs.com, the Mayo Clinic drug database and FDA prescribing information carry no entry for Vesugen, KED or Lys-Glu-Asp, because it has never been approved as a medicine in any jurisdiction. PubMed was searched for adverse events, toxicity and safety of the peptide and of the Khavinson class (no toxicology records returned), and for the quality and safety of peptide products sold through unprescribed online channels, which is where the documented hazard for this compound actually lives. -->

### High 🟥 🟥 🟥

No risk reaches High: Vesugen has never been through a controlled safety trial, so no adverse event has been documented in more than one trial, and no validated safety surrogate has been tracked repeatedly.

### Medium 🟥 🟥

No risk reaches Medium: there is no single controlled trial and no consistent observational dataset reporting adverse events for this compound.

### Low 🟥

#### Substandard, Mislabelled and Endotoxin-Contaminated Product from the Research-Chemical Channel

Vesugen has no pharmaceutical supply chain outside Russia. Laboratory analysis of comparable peptide vials bought from unprescribed online sellers found gross deviation from label and bacterial endotoxin (a fever-inducing bacterial cell-wall fragment) in every sample ([Ashraf et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39509151/)); the channel itself is the hazard ([Belcourt et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39285774/)).

**Magnitude:** Measured purity 7.7–14.37% against a 99% label claim, active content 28.6–38.7% above label, and endotoxin at 2.16–8.95 endotoxin units per milligram in every vial tested; those figures are from semaglutide vials bought through the same seller type, not from Vesugen itself.

#### Oxidant-Promoting Shift and Suppressed Blood-Cell Production ⚠️ Conflicted

In 32 older adults, Vesugen showed oxidant-promoting activity on a light-based assay plus a fall in blood-forming stem cells, suggesting suppressed blood formation ([Meshchaninov et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26390612/)); in animals it was protective under low oxygen ([Kozina, 2008](https://pubmed.ncbi.nlm.nih.gov/18546825/)). Net: one uncontrolled human dataset shows harm the animal work does not.

**Magnitude:** Directionally adverse — the oxidative and blood-count shifts appeared over a standard 10–30 day course in adults aged 41–83 with existing chronic disease; the published report gives no effect-size figure for either change.

### Speculative 🟨

#### Proliferative Risk from Suppressing Cellular Ageing Brakes

KED lowers senescence proteins p16 and p21 in human stem cells ([Sinjari et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31677028/)) and raises Ki-67 in ageing fibroblasts ([Lin'kova et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27259496/)); the same brakes restrain tumours. No human oncology data exist.

#### Injection-Site Reaction and Immune Response with Reconstituted Vials

No case report describes Vesugen injection. The concern is inferred from endotoxin found in similarly sourced vials and from ordinary peptide-injection experience; sterile technique and product provenance drive the risk ([Ashraf et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39509151/)).

#### Unknown Long-Term, Carcinogenicity and Reproductive Safety

No repeat-dose toxicology, carcinogenicity or reproductive study exists. Supplier claims of no side effects rest on uncontrolled observation by the developer, so the basis here is absence of data rather than reported harm.

  
## Risk-Modifying Factors

* **Cancer-related genetics:** No data. In principle, carriers of germline tumour-suppressor variants such as TP53 or BRCA1/2 sit at the sharp end of any agent that lowers p16 and p21, though this has never been tested.

* **Baseline blood counts:** A low white-cell, red-cell or platelet count at baseline leaves no margin against the suppressed blood formation reported in the one human study that measured it ([Meshchaninov et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26390612/)).

* **Sex:** No human sex-stratified safety data exist. The mouse work showed sex-divergent effects on brain structure, so a sex-neutral safety assumption is unsupported rather than established.

* **Pre-existing conditions:** Active or recent cancer, autoimmune disease on immunosuppression, and advanced kidney or liver impairment each remove the safety margin, because clearance and immune effects are unstudied in all of them.

* **Age:** Older adults carry more undiagnosed pre-malignancy and more concurrent medication, so both the proliferative concern and the untested-interaction concern rise with age — yet this is the only group with any human exposure data.

  
## Key Interactions & Contraindications

* **Antiplatelet and anticoagulant drugs — blood thinners (aspirin, clopidogrel, apixaban, warfarin):** Caution, not contraindication. No interaction study exists; any additive bleeding effect is unmeasurable. Mitigation: the existing clotting-time monitoring schedule kept unchanged, with no anticoagulant dose altered because of the peptide.

* **Blood-pressure medicines (lisinopril, losartan, amlodipine):** Caution. Vesugen is claimed to relax and repair vessels; if real, the consequence is orthostatic hypotension (a drop in blood pressure on standing). Mitigation: home readings twice weekly during the first course.

* **Erectile-dysfunction drugs (sildenafil, tadalafil):** Caution. The one human vascular study used Vesugen alone, so combined effect on penile blood flow is untested; theoretical additive vasodilation (vessel widening). Mitigation: a trial of either agent separated from the other by at least two weeks.

* **Over-the-counter analgesics (ibuprofen, naproxen, high-dose aspirin):** Monitor. Non-steroidal anti-inflammatory drugs (pain-relieving drugs that also blunt clotting and raise blood pressure) work against the vascular endpoint. Mitigation: regular use capped, with paracetamol preferred where pain relief is the only goal.

* **Over-the-counter decongestants (pseudoephedrine, phenylephrine):** Monitor. These constrict vessels and raise blood pressure, directly opposing the claimed action and confounding any home blood-pressure signal. Mitigation: avoided during a course, or logged alongside every reading.

* **Supplements that widen vessels (L-Citrulline, beetroot nitrate, garlic extract):** Caution, additive. All lower blood pressure through nitric oxide (a gas the vessel lining makes to relax arteries); stacking makes attribution impossible. Mitigation: one introduced at a time, four weeks apart.

* **Supplements affecting clotting (fish oil, nattokinase, *Ginkgo biloba*, vitamin E):** Caution, additive. Each mildly reduces clotting, and combined with an unquantified vascular agent the net bleeding tendency is unknown. Mitigation: held before dental and surgical procedures per usual practice.

* **Other interventions (statins — cholesterol-lowering drugs, sauna, blood-flow-restriction training):** Monitor. Each independently moves the same vascular readouts, so running them concurrently with a first course removes any chance of attributing a change. Mitigation: new interventions held constant across the course.

**Populations who should avoid Vesugen:**

* **Active or recent malignancy:** cancer treated within the past 5 years, or an untreated pre-cancerous lesion — the compound's proliferative and senescence-suppressing actions have never been tested against tumour biology.

* **Pregnancy and lactation:** no reproductive or developmental toxicology exists at any dose.

* **Age under 18:** no paediatric data; every reported course has been given to adults.

* **Solid-organ transplant recipients on immunosuppression:** unknown immune effects in a group where graft survival depends on stable immune suppression.

* **Advanced kidney or liver failure (estimated filtration rate below 30 mL/min/1.73 m², or Child-Pugh Class C severe liver failure):** clearance of the peptide and its fragments is entirely unstudied.

* **Known hypersensitivity to peptide preparations:** any prior reaction to an injected or sublingual peptide product.

* **Anyone unable to obtain a batch certificate of analysis:** without identity and purity documentation, the actual exposure is unknown.

  
## Risk Mitigation Strategies

* **Batch certificate of analysis before purchase:** protocols in this space require third-party identity and purity documentation (high-performance liquid chromatography ≥98%) plus endotoxin and sterility results for injectables, mitigating the substandard-product risk that dominates real-world harm here.

* **Oral or sublingual route in preference to injection:** capsules remove sterility and endotoxin exposure entirely, mitigating injection-site infection and fever risk, at the cost of an unknown absorbed fraction.

* **Complete blood count at baseline and week four:** the only human harm signal reported for Vesugen was suppressed blood-cell production, so a falling white-cell, red-cell or platelet count serves as the stop criterion.

* **Short, capped courses:** typical use is 10–30 consecutive days, at most three courses a year with eight or more weeks between them, mitigating open-ended exposure to a compound with no repeat-dose toxicology.

* **Cancer history screen before a first course:** no malignancy within 5 years and current age-appropriate screening, mitigating the theoretical proliferative risk of raising Ki-67 while lowering p16 and p21.

* **One variable changed at a time:** statins, exercise, sauna and vessel-widening supplements held constant across the course, mitigating the misattribution that makes a placebo response indistinguishable from a real effect.

* **Proven vascular care left in place:** lipid-lowering therapy, blood-pressure control and exercise continued unchanged, mitigating opportunity cost — the largest realistic harm from an unproven agent.

  
## Therapeutic Protocol

* **Standard oral course (Russian supplement protocol):** one to two capsules delivering 0.1 mg of peptide complex, once or twice daily, 30 minutes before food, for 10–30 consecutive days, repeated two to three times a year.

* **Competing approach — subcutaneous research vials:** Western users reconstitute 20 mg lyophilised (freeze-dried) vials and inject small daily doses. No published human protocol supports this route; the animal work used intraperitoneal (abdominal-cavity) dosing at 400 µg/kg.

* **Originating institution:** both the oral course and the dose come from the St. Petersburg Institute of Bioregulation and Gerontology, which developed and markets the product. No independent clinic has published a different protocol.

* **Time of day:** morning dosing before food is the published instruction. No chronobiology data exist, and the sublingual form is taken away from meals for the same absorption reason.

* **Half-life:** never measured for Vesugen. Tripeptides are generally cleaved within minutes by gut and plasma peptidases, which is why the protocol relies on repeated daily dosing rather than accumulation.

* **Single versus split dosing:** the label permits both. Twice-daily splitting is the more common instruction and is consistent with rapid clearance, though no head-to-head comparison has been run.

* **Genetic polymorphisms (inherited gene variants):** no pharmacogenetic data exist. Variants in SLC15A1, the gene for the intestinal peptide transporter PepT1, would plausibly alter oral uptake; APOE4 (a gene variant raising Alzheimer's risk) touches only the cognitive claims.

* **Sex-based differences:** no human comparison exists. In the Alzheimer's mouse work the spine-density effect reached significance in males only, the sole sex signal anywhere in this literature.

* **Age:** the dosed cohorts run from working-age drivers to patients aged 41–83 with existing disease. Nothing is known about healthy adults under 40, where the proposed mechanism has the least headroom.

* **Baseline biomarkers:** reported effects scale with prior damage — aged and atherosclerotic cultures responded more than young ones — so normal vessel markers predict the smallest expected signal.

* **Pre-existing conditions:** the human protocol was applied in atherosclerotic peripheral disease and in multi-morbid older adults. No dose adjustment for kidney, liver or autoimmune disease has been published.

  
## Discontinuation & Cycling

* **Course-based, not lifelong:** the compound is built around discrete 10–30 day courses repeated a few times a year. No protocol anywhere, vendor or academic, describes indefinite daily intake.

* **Withdrawal effects:** none reported. With no receptor occupancy, no described tolerance and rapid clearance, an abrupt stop has no documented physiological rebound.

* **Tapering:** not applicable. Courses end abruptly by design, and no taper appears in the Russian instructions or in any vendor protocol.

* **Cycling:** cycling is intrinsic to the design rather than a response to tolerance. The stated rationale is that effects on gene expression persist beyond the dosing window, a claim no washout study has tested.

  
## Sourcing and Quality

* **Two distinct supply channels:** Russian-registered food-supplement capsules and sublingual drops on one side, Western "research use only" lyophilised vials on the other. Only the first was used in the human studies, and neither is a regulated medicine.

* **What a certificate of analysis must show:** peptide identity by mass spectrometry, purity of at least 98% by high-performance liquid chromatography, water and acetate content, and, for injectables, bacterial endotoxin and sterility results, each tied to the batch number on the vial.

* **Third-party testing:** independent laboratories such as Janoshik Analytical and Colmaric Analyticals publish batch reports for peptide vendors. A vendor-supplied certificate with no named laboratory and no batch number carries no evidential weight.

* **No reputable brand or compounding pharmacy:** the Russian capsules carry the developing institute's own label, and no Western compounding pharmacy or third-party-audited supplement brand offers the compound; the research-chemical vendors that do are unaudited and name no manufacturer.

* **Formulation:** the oral product is a peptide complex on a carrier rather than pure tripeptide, so a 0.1 mg capsule and a 20 mg research vial are not comparable units and cannot be dose-converted.

* **Storage:** lyophilised peptide is stable for months at −20 °C. Once reconstituted in bacteriostatic water it is typically discarded after three to four weeks; capsules follow the printed expiry date.

  
## Practical Considerations

* **Time to effect:** the human studies measured outcomes at the end of a full 10–30 day course, the vascular series comparing flow before and after that completed course ([Kitachev et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25051774/)). Nothing in the literature supports a perceptible effect within days.

* **Common pitfalls:** stacking several bioregulators simultaneously, injecting a compound whose only human data are oral, and treating vendor marketing copy as though it were the primary literature.

* **Regulatory status:** unapproved as a medicine by both the United States Food and Drug Administration and the European Medicines Agency; a registered food supplement in Russia; sold elsewhere labelled not for human consumption.

* **Structural funding bias:** generic statins and blood-pressure drugs cost a few dollars a month, so insurers and national health systems have no incentive to fund trials of a costlier peptide course; none has been registered, making the evidence gap partly a funding gap.

* **Cost and access:** a 20-capsule oral course runs roughly 40–70 US dollars and a 20 mg research vial 30–60. Neither is prohibitive, but neither is obtainable through a pharmacy in most countries.

  
## Interaction with Foundational Habits

* **Sleep:** No direct interaction. Vesugen has no sedative or stimulant action and no reported effect on sleep architecture. The indirect link runs the other way: short sleep worsens endothelial function, so poor sleep during a course will obscure any vascular signal. Dosing time relative to bedtime is unconstrained.

* **Nutrition:** Direct, absorption-level interaction. The published instruction is dosing 30 minutes before food, on the assumption that competing dietary peptides and amino acids reduce uptake through the intestinal peptide transporter. No feeding study has confirmed this. High-protein meals are the plausible competitor; nothing needs excluding from the diet.

* **Exercise:** Potentiating, unmeasured. Aerobic training raises nitric oxide availability and improves vessel-lining function through the same endpoint Vesugen targets, so the two are directionally aligned. That alignment is also the confounder: starting a course and a training block together makes attribution impossible. No blunting of adaptation is reported or expected.

* **Stress management:** Indirect. The 2015 human study ([Meshchaninov et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26390612/)) included people with lasting brain impairment and reported improved central nervous system activity, but measured no stress hormone. Chronic stress raises blood pressure and impairs the vessel lining, so unmanaged stress works against the intended endpoint. No cortisol data exist for this compound.

  
## Monitoring Protocol & Defining Success

Because no trial has defined a response marker for Vesugen, monitoring borrows from standard vascular-risk assessment and treats the individual as their own control. Before a first course, a baseline set is drawn: a lipid panel with apolipoprotein B, lipoprotein(a) once in a lifetime, high-sensitivity C-reactive protein, fasting glucose and insulin, haemoglobin A1c, a full blood count, kidney and liver panels, and a resting blood pressure average. Two structural measures anchor the vascular question itself — carotid artery ultrasound thickness and either ankle–brachial index or pulse-wave velocity — since these change slowly enough to be meaningful across years rather than weeks.

Ongoing testing follows a simple cadence: the blood count and inflammatory markers are repeated at four weeks of the first course, the full panel at three months, then every six to twelve months, with the structural imaging repeated no more often than every one to two years.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Apolipoprotein B | < 60 mg/dL for aggressive prevention; < 80 mg/dL otherwise | Best single count of artery-clogging particles | Conventional labs flag only above 90–130 mg/dL; non-fasting sample acceptable |
| Lipoprotein(a) | < 30 mg/dL (< 75 nmol/L) | Inherited vascular risk this compound cannot plausibly move | Measured once in a lifetime; molar (nmol/L) assay preferred; unchanged by diet |
| High-sensitivity C-reactive protein | < 0.8 mg/L | Vessel-wall inflammation, the plausible target of an endothelial agent | Conventional cut-off is < 3 mg/L; repeated if raised, to exclude intercurrent infection |
| Fasting insulin | 2–5 µIU/mL | Insulin resistance is a primary driver of vessel-lining dysfunction | Conventional labs flag only above 25 µIU/mL; paired with fasting glucose after a 12-hour fast |
| Haemoglobin A1c | 4.8–5.4% | Glucose-driven damage to the vessel wall over the prior three months | Conventional cut-off is < 5.7%; falsely low when red cells are short-lived; paired with fructosamine if anaemic |
| Complete blood count with differential | Within the laboratory reference range and not falling from personal baseline | The one human harm signal reported for this compound was suppressed blood-cell production | Drawn at baseline and again at four weeks of the first course |
| Homocysteine | 5–7 µmol/L | Direct toxicity to the vessel lining, and a modifiable input | Fasting draw, separate tube; the conventional range runs to 15 µmol/L |
| Blood pressure, home average | < 120/75 mmHg | The functional readout of vessel tone | Conventional treatment target is < 130/80 mmHg; averaged over seven consecutive mornings, seated and rested five minutes |
| Carotid intima–media thickness | Below the 50th percentile for age and sex | Structural vessel ageing — the outcome the compound claims to address | Ultrasound of the neck artery wall; operator-dependent; repeated at most every 1–2 years |
| Ankle–brachial index | 1.00–1.30 | Detects narrowing in the leg arteries, the population actually studied | Ratio of ankle to arm blood pressure; values above 1.30 indicate stiff, calcified vessels |
| Carotid–femoral pulse-wave velocity | < 7.5 m/s under age 50; < 10 m/s over 60 | Arterial stiffness, the most direct measure of vascular age | No established target for change on this compound; tracked against the individual's own baseline |
| Estimated glomerular filtration rate | > 90 mL/min/1.73 m² | Kidney filtration mirrors the health of the smallest vessels | Conventional labs flag only below 60 mL/min/1.73 m²; creatinine-based estimate; cystatin C used if muscle mass is unusually high or low |

Qualitative markers worth tracking alongside the laboratory set:

* Exercise tolerance and recovery time after a standard effort
* Claudication distance (how far someone walks before calf pain begins), where peripheral disease is present
* Cold hands and feet, and how quickly colour returns after cold exposure
* Sexual function, the endpoint of the single human vascular study
* Energy through the afternoon, and cognitive clarity on familiar tasks
* Sleep quality and morning restedness

  
## Emerging Research

* **No registered trial of Vesugen exists:** searches of ClinicalTrials.gov by intervention and free text for Vesugen, Lys-Glu-Asp and Khavinson return zero studies. The entire human record is unregistered Russian work published as journal abstracts.

* **Short peptides and induced-neuron senescence:** [Sakhenberg et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41020860/) reported that KED cut the cell-cycle marker p21 by 15% and beta-galactosidase (an enzyme whose activity marks aged cells) by 1.51–2.4-fold in stem cells converted into cortical neurons — a newer model, still with no human endpoint.

* **Dendrite protection in human-derived neurons:** [Kraskovskaya et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39518916/) found KED at 10 µg/mL increased primary dendrite number and total dendrite length in neurons derived from elderly donors' skin cells, while leaving mitochondrial and lysosomal activity unchanged.

* **Vascular ageing biology without the peptide:** the observational [VITAL cohort (NCT07122427)](https://clinicaltrials.gov/study/NCT07122427), 30 participants at a French university hospital, compares arterial and venous graft ageing markers across age bands — the endpoint any future Vesugen trial would need.

* **Comparator interventions already in trials:** [NCT05483465](https://clinicaltrials.gov/study/NCT05483465), a phase 4 study of nicotinamide adenine dinucleotide precursor supplementation in 214 participants, and [NCT07469475](https://clinicaltrials.gov/study/NCT07469475), a phase 1/2 study of a daily supplement on plasminogen activator inhibitor-1 in 35 participants, show what a registered vascular-ageing trial looks like.

* **What would weaken the case:** an independent laboratory failing to reproduce the endothelial Ki-67 effect, or a pharmacokinetic (drug-movement) study showing the intact tripeptide never reaches plasma after oral dosing, would remove the mechanism's foundation; [Ashapkin et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32399807/) is the closest gene-expression work to date.

* **What would strengthen it:** a randomised, placebo-controlled trial using pulse-wave velocity or carotid thickness as the primary endpoint, run outside St. Petersburg, is the single study that would lift any benefit above the Low grade assigned here.

  
## Conclusion

Vesugen is a three-part protein fragment sold for blood-vessel health, built on the idea that a molecule this small can slip into a cell nucleus and adjust which genes are active. In laboratory dishes and aged animal tissue that idea holds up reasonably well: cells from older vessels behave more like young ones, and markers of cellular ageing move in the expected direction. Almost none of that has been carried into people under conditions that could rule out wishful thinking.

The human record is several small studies — older adults with circulatory or brain problems, and workers under occupational strain — none with a comparison group, and all run by or alongside the St. Petersburg institute that created the compound, holds the patent and sells it. That single-source pattern is the most important fact about the evidence base, and it cuts both ways: nothing has been disproven either, because nobody outside that group has tried to repeat the work.

Against thin benefit evidence sits a concrete and well-documented downside that has nothing to do with the molecule itself. Outside Russia it is bought from suppliers that state their product is not for human use, and independent testing of that supply channel has repeatedly found vials whose contents bear little resemblance to the label. For someone already doing the proven things for their arteries, the realistic question is not whether the idea is interesting but whether anything measurable is known — and at present very little is.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**